Investing Profile

Andrew Levin

VC

Photo of Andrew Levin, Managing Partner at RA Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RA Capital Managing Partner
11
CompanyStageDateRound SizeTotal Raised
Metagenomi
Series BJan 2022$180M
Series ANov 2020$75M
$280M
Co-investors: Sebastian Bernales (Humboldt Fund), Kyle Kurpinski (Tencent Holdings)
Expansion Therapeutics
Series BSep 2021$80M
Series AJan 2018$55M
$140M
Co-investors: Scott Rocklage (5am Ventures), Beth Seidenberg (Kleiner Perkins)
Delix Therapeutics
Series ASep 2021$70M
$70M
Co-investors: Matias Serebrinsky (PsyMed Ventures), Vasudev Bailey (Artis Ventures (AV))
Eliem Therapeutics
Series BMay 2021$60M
Series AMar 2021$80M
$140M
Co-investors: Liam Ratcliffe (Access Biotechnology)
Alchemab Therapeutics
Series AApr 2021£60M
£60M
Co-investors: Houman Ashrafian (SV Health Investors)
Arvinas
Series CApr 2018$55M
Series BOct 2015$42M
$110M
Co-investors: Kush Parmar (5am Ventures), Colleen Cuffaro (Canaan Partners), Tim Shannon (Canaan Partners), Stephen Squinto (OrbiMed), Jakob Loven (Nextech Invest), Daniel Wagner (Connecticut Innovations), Liam Ratcliffe (Access Biotechnology)
Synthorx
Series BJul 2016$10M
$73M
Co-investors: Peter Thompson (OrbiMed)